Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

BrafPanc: A Phase II Trial of Binimetinib in Combination With Encorafenib in Patients With Pancreatic Malignancies and a Somatic BRAFV600E Mutation

NCT04390243 is registered in ClinicalTrials.gov with Academic and Community Cancer Research United as lead sponsor.

NCT NCT04390243
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04390243 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
BrafPanc: A Phase II Trial of Binimetinib in Combination With Encorafenib in Patients With Pancreatic Malignancies and a Somatic BRAFV600E Mutation
Lead sponsor
Academic and Community Cancer Research United
Phase
Phase 2
Overall status
Terminated
Start date
November 16, 2020
Completion date
November 1, 2023
Enrollment
6 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced pancreatic carcinoma, metastatic pancreatic carcinoma, recurrent pancreatic carcinoma, stage iii pancreatic cancer ajcc v8, stage iv pancreatic cancer ajcc v8